ImmuPharma (LON:IMM) Shares Up 27.3% - Here's What Happened

Key Points

• ImmuPharma's share price surged 27.3% on a single trading day, reaching a high of GBX 12.75 ($0.17) before closing at GBX 12.60 ($0.17).
• The company's recent trading volume was approximately 4.5 million shares, which is a 46% decline from its average daily volume of 8.4 million shares.
• ImmuPharma reported a net margin of 3,519.56% and a negative return on equity of 131.41%, highlighting significant financial volatility.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was up 27.3% on Friday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares changed hands during trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Trading Up 27.3%

The firm's 50 day moving average is GBX 7.70 and its two-hundred day moving average is GBX 4.29. The firm has a market cap of £63.34 million, a P/E ratio of -1,415.73 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.